secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuwellis, Inc. (NUWE)
CIK:        0001506492
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001140361-24-011633
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuwellis Q4 revenue record $2.6M (+9% YoY); net loss $7.9M on financing costs; pediatric sales up 35%
--------------------------------------------------------------------------------

- Q4 revenue $2.6M (+9% YoY); full year revenue $8.9M (+4% YoY).
- Net loss attributable to common $7.9M ($2.24/share) includes $4.4M financing-related charges; prior year net loss $1.9M.
- Pediatric revenue +35% YoY in Q4; utilization +28%, console sales +49%, 4 new accounts added.
- Cash $3.8M, no debt; CEO targets 40% cash-burn reduction and expects capital raise in 2024.
- New products launched: 12cm dELC catheter, Quelimmune pediatric device; IDE submission for Vivian device planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506492/000114036124011633/0001140361-24-011633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506492/000114036124011633/ef20023378_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-011633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer